Logan Lutton

In this conversation, Johns Hopkins researchers describe a newly identified population of brainstem neurons that are crucial for selective attention in mice and may offer fresh insight into ADHD in humans.

A former radiation oncologist turned chief medical officer, Rex Hoffman, M.D., MBA, has spent the past several years expanding his leadership footprint across Providence Holy Cross Medical Center’s health system while authoring multiple books aimed at helping physicians navigate the transition into executive roles.

A new study in JAMA Network Open projects that the number of Medicare beneficiaries 65 and older living with HIV will grow from approximately 122,000 to 194,000 by 2035, driving cumulative Medicare costs of $187.2 billion, with antiretroviral therapy alone accounting for 63% of that spending.

Marc Elia of Invyvid explains the difference between vaccines and monoclonal antibodies.

A phase 3b trial found that Otsuka's centanafadine significantly improved both ADHD symptoms and anxiety symptoms in adults with ADHD and comorbid anxiety, with effects emerging as early as week 1 and holding through 8 weeks, as the drug awaits an FDA decision expected July 24, 2026.

In this interview, Marc Elia argues that monoclonal antibodies like VYD2311 offer a fundamentally different approach to COVID-19 prevention than vaccines, delivering protective antibodies directly rather than triggering an immune response, which he says could improve tolerability.

Built from the experiences of patients, advocates and clinicians, a new MASH patient journey map offers a roadmap for navigating diagnosis and highlights the need for greater public understanding of the disease.

Financial sustainability and innovation are interdependent, as clinician-led contracting strategies that improve outcomes generate savings that fund further innovation.

Lung cancer has shifted from a rare, smoking-driven disease to one increasingly seen in young non-smokers, especially women, with possible links to pesticide exposure from otherwise “healthy” diets.

In this discussion, Jorge Nieva, M.D., professor of clinical medicine at the University of Southern California Norris Comprehensive Cancer Center, explores how pesticide exposure from otherwise “healthy” diets may help explain the rise of early-onset lung cancer in non-smokers.

Skinvive by Juvéderm recently received FDA approval as the first hyaluronic acid injectable indicated for reducing horizontal neck lines, with 74.8% of trial participants achieving clinically significant improvement at one month.

The FDA has expanded Capvaxive approval to include 2- to 17-year-olds at increased risk of pneumococcal disease, making it the only pneumococcal conjugate vaccine approved for this population in the United States.

A CDC-led test-negative case-control study using the VISION network found that the 2024-2025 COVID-19 vaccine reduced the odds of medically attended COVID-19 in adults, with an effectiveness of 26% against emergency department/urgent care encounters, 35% against hospitalization and 41% against critical illness, benefits that held up in older adults and immunocompromised patients but waned over time since vaccination.

The FDA has approved the sunscreen ingredient bemotrizinol, which blocks both UVA and UVB rays.

Things got messy fast after ADA security pulled researchers out of its 2026 conference for passing around an anti-NIH-cuts editorial — cue a walkout, a couple of high-profile resignations and a CEO apology video to try to smooth things over.

A University of Pittsburgh study found that one RSV shot during pregnancy cut the odds of a newborn landing in the hospital by nearly 70%.

Two food access interventions, one of which combined grocery delivery with community health worker coaching, showed significant improvements in diabetes control, food insecurity and overall health outcomes across both youth and adult populations.

The FDA has approved a new maintenance dosing schedule for Ebglyss that reduces injections to as few as six per year for patients with moderate to severe atopic dermatitis.

An individualized mRNA neoantigen vaccine added to pembrolizumab reduced the risk of recurrence by 49% and distant metastasis by 59% in resected high-risk melanoma, with benefits holding through five years of follow-up in a phase 2b trial.

Cambridge researchers have completed the first human trial of pEVAC-PS, an AI-designed vaccine intended to protect against the entire family of Sarbeco viruses, finding it safe and well tolerated across all dose levels, with modest immune responses that warrant further investigation in a phase 2 trial.

Shame, fueled by stigma, can deter care for HIV patients; recognizing it and responding compassionately can reduce harm, according to Abigail Bachelder, M.P.H., Ph.D., associate psychiatry professor at Boston University Chobanian & Avedisian School of Medicine.

Abigail Batchelder, M.P.H., Ph.D., clinical psychologist and associate professor at Boston University, explains the effect that shame can have on the healthcare outcomes of HIV patients and why “explicit compassion” is a step in the right direction when treating these individuals.

By partnering with pastors to navigate religious taboos and collaborating with public health agencies, researchers Jannette Berkley-Patton, Ph.D., and Kathryn Derose, Ph.D., demonstrated that African American churches — long-standing pillars of their communities — can serve as trusted, effective sites for HIV testing that reach not only congregants but also the broader community, helping to address the disproportionate impact of HIV on African Americans.

The FDA has approved Epiduo for over-the-counter use, a combination acne gel previously available only by prescription, a decision experts say could expand access to effective treatment for the millions of Americans who face cost and logistical barriers to dermatological care.

A phase 3 clinical trial presented at ASCO 2026 found that combining talazoparib with enzalutamide reduced the risk of cancer progression by 52% compared with enzalutamide alone in prostate cancer patients with specific DNA repair gene mutations, with even greater benefit seen in those carrying BRCA mutations.

A new investigational combination therapy for advanced KRAS G12C-mutant non-small cell lung cancer showed "highly promising" results with “manageable” side effects, according to the study’s lead author.

Ferdinandos Skoulidis, M.D., Ph.D., explains what’s next for this treatment for patients with previously untreated advanced or metastatic KRAS G12C-mutated non-small cell lung cancer.

Divarasib plus pembrolizumab shows strong responses in patients with advanced KRAS G12C+ non-small cell lung cancer, according to the results of the Krascendo 170 study, presented today at ASCO 2026.

Eli Lilly and Company is acquiring three vaccine companies to expand its reach into infectious disease research and prevention.

Women with high-grade serous ovarian cancer who fasted around chemotherapy sessions had lower insulin levels, improved chemotherapy responses and potentially longer progression-free survival compared with patients who ate normally, according to findings from an Italian study presented at the 2026 American Society of Clinical Oncology Annual Meeting.